- Overview and rationale for targeting TRK in solid tumors and implementing NTRK testing in the clinic
- Methods for identifying NTRK fusions
- Clinical data and current indications for TRK inhibitors in multiple cancer settings
- Overcoming acquired resistance with second-generation TRK inhibitors
- Ongoing clinical trials and review of key ASCO 2021 abstracts
- Panel discussion: Evolving diagnostic and treatment algorithms
George Demetri, MD
Professor of Medicine
Harvard Medical School
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York
The goal of this program is to improve the knowledge and competence of learners to test for NTRK gene fusion and integrate TRK inhibitors into the treatment of patients with cancer.
This educational program is intended for physicians and other healthcare professionals who treat patients with cancer.
Upon completion of this activity, participants should be able to:
- Describe the biology of and rationale for targeting cancers containing NTRK fusions
- Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
- Implement TRK inhibitor therapy for appropriate patients with cancer
- Develop treatment strategies for patients who develop acquired resistance to first-generation TRK inhibitor therapy
- Refer adult and pediatric patients to ongoing late-phase clinical trials of TRK inhibitors
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.